Haleon plc

Equities

HLN

GB00BMX86B70

Pharmaceuticals

Market Closed - London S.E. 11:35:18 2024-04-25 am EDT 5-day change 1st Jan Change
331.5 GBX +0.58% Intraday chart for Haleon plc +3.21% +3.06%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Moody’s Affirms Haleon’s Ratings on Strong Operating Performance MT
Haleon: a new CFO at the end of October CF
Haleon appoints Tate & Lyle's finance chief as CFO from November AN
Haleon Taps Tate & Lyle Finance Chief Dawn Allen as CFO DJ
British Healthcare Company Haleon Names Tate & Lyle CFO as New Finance Chief MT
Haleon names Dawn Allen as CFO RE
Haleon plc Announces Management Changes CI
Haleon plc Announces Chief Financial Officer Changes CI
HSBC Starts Haleon Coverage with Buy Rating MT
HSBC likes Haleon, cuts Flutter to 'hold' AN
Embattled Hipgnosis Songs Fund agrees takeover AN
HALEON : Haleon on-track to deliver healthy and steady shareholder returns Alphavalue
Deutsche Bank Trims Haleon PT, Keeps Hold Rating MT
Futura Medical hails results as erectile dysfunction drug drives sales AN
Exane BNP raises Shell to 'outperform' AN
Barclays Trims Haleon PT, Keeps Overweight Rating MT
Barclays raises Halma to 'overweight' AN
Kepler Cheuvreux Lifts Haleon PT, Keeps Hold Rating MT
Bernstein starts AstraZeneca at 'outperform' AN
Global IPO revival lags first quarter share sales as markets rally RE
Haleon buys back shares worth GBP315 million from Pfizer AN
Repeat & Correct : Pfizer to Raise Around $3.5 Billion From Haleon Shares Sale -- Update DJ
Haleon Says Pfizer to Cut Stake to 23% After Pricing Upsized Secondary Offering of Haleon Shares MT
Pfizer to Raise Around $4.27 Billion From Haleon Shares Sale -- Update DJ
Haleon to buy back shares from Pfizer for GBP315 million AN
Chart Haleon plc
More charts
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.315 GBP
Average target price
3.594 GBP
Spread / Average Target
+8.41%
Consensus
  1. Stock Market
  2. Equities
  3. HLN Stock
  4. News Haleon plc
  5. Haleon Sees First-quarter Earnings Growth as Pfizer Pushes Ahead With Gradual Stake Sale